Evidence map›Paper›PMID 31195240›Full record

ArticleiScience2019

Serum Deprivation of Mesenchymal Stem Cells Improves Exosome Activity and Alters Lipid and Protein Composition.

Reka Agnes Haraszti, Rachael Miller, Michelle L Dubuke, Hannah E Rockwell, Andrew H Coles, Ellen Sapp, Marie-Cecile Didiot, Dimas Echeverria, Matteo Stoppato, Yves Y Sere and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Round window membrane extracellular vesicles facilitate inner ear drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Reka Agnes HarasztiRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA. Electronic address: rharaszti@gmail.com.
Rachael MillerRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA; Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
Michelle L DubukeMass Spectrometry Facility, Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Shrewsbury, MA, USA.
Hannah E RockwellBERG LLC, Framingham, MA, USA.
Andrew H ColesRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.
Ellen SappMass General Institute for Neurodegenerative Disease, Boston, MA, USA.
Marie-Cecile DidiotRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.
Dimas EcheverriaRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.
Matteo StoppatoMassBiologics, Boston, MA, USA.
Yves Y SereMassBiologics, Boston, MA, USA.
John LeszykMass Spectrometry Facility, Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Shrewsbury, MA, USA.
Julia F AltermanRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.
Bruno M D C GodinhoRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.
Matthew R HasslerRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.
Justice McDanielBERG LLC, Framingham, MA, USA.
Niven R NarainBERG LLC, Framingham, MA, USA.
Rachel WollacottMassBiologics, Boston, MA, USA.
Yang WangMassBiologics, Boston, MA, USA.
Scott A ShafferMass Spectrometry Facility, Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Shrewsbury, MA, USA.
Michael A KiebishBERG LLC, Framingham, MA, USA.
Marian DiFigliaMass General Institute for Neurodegenerative Disease, Boston, MA, USA.
Neil AroninRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA; Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA. Electronic address: neil.aronin@umassmed.edu.
Anastasia KhvorovaRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA; Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA. Electronic address: anastasia.khvorova@umassmed.edu.
University of Massachusetts Chan Medical School · USMassachusetts General Hospital · US

Funding

University of Massachusetts Center for Clinical and Translational ScienceUL1TR000161 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUZURIAGA, KATHERINE F · 2012 to 2015
$11.0M
Exosome based therapeutics in Huntington's diseaseUH3TR000888 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ARONIN, NEIL, KHVOROVA, ANASTASIA · 2015 to 2017
$3.0M
Inter and intra-cellular trafficking pathways for natural and therapeutic RNAsR01GM108803 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KHVOROVA, ANASTASIA · 2014 to 2018
$2.0M
Exosome based therapeutics in Huntington's diseaseUH2TR000888 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ARONIN, NEIL · 2013 to 2014
$1.1M
Mid-Scale RNA Synthesis, Purification and Quality Control SystemS10OD020012 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KHVOROVA, ANASTASIA · 2015 to 2015
$563k
NCATS NIH HHS UH2 TR000888NCATS NIH HHS UH3 TR000888NCATS NIH HHS UL1 TR000161NIGMS NIH HHS R01 GM108803NIH HHS S10 OD020012
6 · The paper itself

Abstract

Exosomes can serve as delivery vehicles for advanced therapeutics. The components necessary and sufficient to support exosomal delivery have not been established. Here we connect biochemical composition and activity of exosomes to optimize exosome-mediated delivery of small interfering RNAs (siRNAs). This information is used to create effective artificial exosomes. We show that serum-deprived mesenchymal stem cells produce exosomes up to 22-fold more effective at delivering siRNAs to neurons than exosomes derived from control cells. Proteinase treatment of exosomes stops siRNA transfer, indicating that surface proteins on exosomes are involved in trafficking. Proteomic and lipidomic analyses show that exosomes derived in serum-deprived conditions are enriched in six protein pathways and one lipid class, dilysocardiolipin. Inspired by these findings, we engineer an "artificial exosome," in which the incorporation of one lipid (dilysocardiolipin) and three proteins (Rab7, Desmoplakin, and AHSG) into conventional neutral liposomes produces vesicles that mimic cargo delivering activity of natural exosomes.

Indexed as

BiochemistryBiological SciencesLipidomicsMolecular BiologyProteomics

Identifiers

PMID31195240
PMCPMC6562145
OpenAlexW2947838112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.